Novavax files for authorisation of COVID-19 shot among adolescents in Britain
The drugmaker in late January filed for Emergency Use Authorisation (EUA) of its COVID-19 shot for adults in the US
Novavax said yesterday it had filed an application with Britain’s drugs regulator for the authorisation of its COVID-19 vaccine among adolescents aged 12 years and older.
Britain had in February cleared the two-dose vaccine, Nuvaxovid, for use in adults amid a spike in cases fuelled by the Omicron variant of the coronavirus.
Novavax’s submission includes data from a late-stage trial in the US, where the vaccine showed 80 per cent efficacy among adolescents when Delta was the dominant variant in the country.
The drugmaker in late January filed for Emergency Use Authorisation (EUA) of its COVID-19 shot for adults in the US.
The US Food and Drug Administration (FDA) plans to hold several meetings of its outside panel of experts in June to discuss authorisation requests submitted by multiple COVID-19 vaccine manufacturers including Novavax.
Edits by EP News Bureau